Addex Therapeutics Ltd (ADXN)

Addex Therapeutics Income Statement

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	0.4	1.61	1.42	2.92	3.61
Other Revenue	0.01	0	0.02	0.24	0.27
Revenue	0.41	1.62	1.44	3.15	3.88
Revenue Growth (YoY)	-74.64%	11.92%	-54.18%	-18.71%	36.90%
Cost of Revenue	0.85	1.19	8.23	12.82	10.37
Gross Profit	-0.44	0.43	-6.78	-9.67	-6.49
Selling, General & Admin	2.31	2.67	3.76	5.84	5.75
Operating Expenses	2.31	2.67	3.76	5.84	5.75
Operating Income	-2.76	-2.24	-10.54	-15.51	-12.24
Interest Expense	-0	-0	-0.03	-0.06	-0.07
Interest & Investment Income	0.01	0.06	0.03	0.01	0.04
Earnings From Equity Investments	-2.18	-	-	-	-
Currency Exchange Gain (Loss)	0.02	-0.32	-0.26	0.21	-0.58
EBT Excluding Unusual Items	-4.91	-2.5	-10.8	-15.35	-12.86
Pretax Income	-4.91	-2.5	-10.8	-15.35	-12.86
Earnings From Continuing Operations	-4.91	-2.5	-10.8	-15.35	-12.86
Earnings From Discontinued Operations	11.97	-8.06	-10	-	-
Net Income	7.06	-10.56	-20.8	-15.35	-12.86
Net Income to Common	7.06	-10.56	-20.8	-15.35	-12.86
Shares Outstanding (Basic)	98	74	45	34	27
Shares Outstanding (Diluted)	98	74	45	34	27
Shares Change (YoY)	32.04%	64.45%	32.43%	27.88%	0.96%
EPS (Basic)	0.07	-0.14	-0.46	-0.45	-0.48
EPS (Diluted)	0.07	-0.14	-0.46	-0.45	-0.48
Free Cash Flow	-5.37	-8	-16.44	-14.74	-12.24
Free Cash Flow Per Share	-0.06	-0.11	-0.36	-0.43	-0.46
Gross Margin	-108.35%	26.62%	-	-	-167.41%
Operating Margin	-671.94%	-138.70%	-729.50%	-491.74%	-315.62%
Profit Margin	1720.75%	-652.75%	-1439.78%	-486.85%	-331.48%
Free Cash Flow Margin	-1310.80%	-494.64%	-1137.59%	-467.34%	-315.52%
EBITDA	-2.56	-2.23	-10.53	-15.16	-11.86
EBITDA Margin	-	-137.97%	-	-	-
D&A For EBITDA	0.19	0.01	0.01	0.35	0.38
EBIT	-2.76	-2.24	-10.54	-15.51	-12.24
EBIT Margin	-	-138.70%	-	-	-

Updated Nov 22, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q